Susan K. Loftin

5.7k citations

22 papers · 4.5k indexed · 4 hit papers · h-index 18

Co-authors: Cliona M. Rooney Robert A. Krance Catherine Y. Ng Malcolm K. Brenner Helen E. Heslop Colton A. Smith Yan‐jun Gan John W. Sixbey
Topics: Parkinson's Disease Mechanisms and Treatments (12 papers)Neurological disorders and treatments (9 papers)Viral-associated cancers and disorders (6 papers)
Cited by: Oncology Immunology Epidemiology
Journals: The Lancet Nature Medicine Blood
Partner nations: United States Italy Lebanon

In The Last Decade

Susan K. Loftin

22 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1995 942 citations Cliona M. Rooney, Catherine Y. Ng et al. The Lancet profile →
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

1998 859 citations Cliona M. Rooney, Colton A. Smith et al. Blood profile →
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

2003 695 citations Norihiko Watanabe, Maya Gavrieli et al. Nature Immunology profile →
Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes

1996 668 citations Helen E. Heslop, Catherine Y. Ng et al. Nature Medicine profile →

Peers

Countries citing papers authored by Susan K. Loftin

Since Specialization

Citations

This map shows the geographic impact of Susan K. Loftin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan K. Loftin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan K. Loftin more than expected).

Fields of papers citing papers by Susan K. Loftin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan K. Loftin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan K. Loftin. The network helps show where Susan K. Loftin may publish in the future.

Co-authorship network of co-authors of Susan K. Loftin

This figure shows the co-authorship network connecting the top 25 collaborators of Susan K. Loftin. A scholar is included among the top collaborators of Susan K. Loftin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan K. Loftin. Susan K. Loftin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia 2022 ·Annals of Clinical and Translational Neurology ·Rebecca L. Miller,Dhruva D. Dhavale,(unknown),(unknown),Jialu Liu,Erin Franklin,Chandana Buddhala,Susan K. Loftin,John R. Cirrito,Richard J. Perrin,Nigel J. Cairns,Meghan C. Campbell,Joel S. Perlmutter,Paul T. Kotzbauer	28
2	Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques 2018 ·PLoS ONE ·Joshua S. Shimony,Jerrel Rutlin,Morvarid Karimi,Linlin Tian,Abraham Z. Snyder,Susan K. Loftin,Scott A. Norris,Joel S. Perlmutter	13
3	Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease 2015 ·Annals of Clinical and Translational Neurology ·Chandana Buddhala,Susan K. Loftin,(unknown),Nigel J. Cairns,Meghan C. Campbell,Joel S. Perlmutter,Paul T. Kotzbauer	141
4	In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment 2014 ·Brain Research ·Linlin Tian,Morvarid Karimi,Christopher Brown,Susan K. Loftin,Joel S. Perlmutter	8
5	Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates 2014 ·Annals of Neurology ·Laura L. Dugan,(unknown),Kevin L. Quick,(unknown),Morvarid Karimi,Christopher Brown,Susan K. Loftin,(unknown),Stephen M. Moerlein,John Polich,Samer D. Tabbal,Jonathan W. Mink,Joel S. Perlmutter	59
6	Low nigrostriatal reserve for motor parkinsonism in nonhuman primates 2012 ·Experimental Neurology ·Samer D. Tabbal,(unknown),Morvarid Karimi,Christopher Brown,Susan K. Loftin,Joel S. Perlmutter	32
7	Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys 2012 ·Experimental Neurology ·Christopher Brown,Meghan C. Campbell,Morvarid Karimi,Samer D. Tabbal,Susan K. Loftin,Lin Tian,Stephen M. Moerlein,Joel S. Perlmutter	55
8	No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease 2012 ·PLoS ONE ·Linlin Tian,Morvarid Karimi,Susan K. Loftin,Christopher Brown,(unknown),Jinbin Xu,Robert H. Mach,Joel S. Perlmutter	28
9	Intravenous levodopa administration in humans based on a two-compartment kinetic model 2006 ·Journal of Neuroscience Methods ·Mollie Gordon,Joanne Markham,Johanna M Hartlein,Jonathan M. Koller,Susan K. Loftin,Kevin J. Black	9
10	Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid 2006 ·Journal of Chromatography B ·Morvarid Karimi,Juanita L. Carl,Susan K. Loftin,Joel S. Perlmutter	76
11	Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2 2003 ·Biochemical and Biophysical Research Communications ·Maya Gavrieli,Norihiko Watanabe,Susan K. Loftin,Theresa L. Murphy,Kenneth M. Murphy	152
12	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1breakdown → 2003 ·Nature Immunology ·Norihiko Watanabe,Maya Gavrieli,John R. Šedý,Jianfei Yang,Francesca Fallarino,Susan K. Loftin,Michelle A. Hurchla,Natalie Zimmerman,Julia Sim,Xingxing Zang,Theresa L. Murphy,John H. Russell,James P. Allison,Kenneth M. Murphy	695
13	Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients 1998 ·Blood ·Cliona M. Rooney,Colton A. Smith,Catherine Y. Ng,Susan K. Loftin,John W. Sixbey,Yan‐jun Gan,Deo Kumar Srivastava,Laura C. Bowman,Robert A. Krance,Malcolm K. Brenner,Helen E. Heslop	285
14	Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipientsbreakdown → 1998 ·Blood ·Cliona M. Rooney,Colton A. Smith,Catherine Y. Ng,Susan K. Loftin,John W. Sixbey,Yan‐jun Gan,Deo Kumar Srivastava,Laura C. Bowman,Robert A. Krance,Malcolm K. Brenner,Helen E. Heslop	859
15	Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytesbreakdown → 1996 ·Nature Medicine ·Helen E. Heslop,Catherine Y. Ng,(unknown),(unknown),Susan K. Loftin,Robert A. Krance,Malcolm K. Brenner,Cliona M. Rooney	668
16	Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative Disease 1995 ·Journal of Hematotherapy ·(unknown),Catherine Y. Ng,Helen E. Heslop,Martha Holladay,(unknown),(unknown),Susan K. Loftin,(unknown),Malcolm K. Brenner,Cliona M. Rooney	103
17	Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationbreakdown → 1995 ·The Lancet ·Cliona M. Rooney,(unknown),Catherine Y. Ng,Susan K. Loftin,Colton A. Smith,(unknown),Robert A. Krance,Malcolm K. Brenner,(unknown),(unknown),(unknown)	942
18	Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease 1995 ·British Journal of Haematology ·Cliona M. Rooney,Susan K. Loftin,Martha Holladay,Malcolm K. Brenner,Robert A. Krance,(unknown)	193
19	Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts 1992 ·Cancer Chemotherapy and Pharmacology ·Janet A. Houghton,Larry G. Williams,Susan K. Loftin,Pamela J. Cheshire,Christopher L. Morton,Peter J. Houghton,(unknown),Jacques Jolivet	25
20	Accumulation, Intracellular Metabolism, and Antitumor Activity of High- and Low-Dose Methotrexate in Human Osteosarcoma Xenografts 1990 ·PubMed ·William H. Meyer,Susan K. Loftin,Janet A. Houghton,Peter J. Houghton	4

About Susan K. Loftin

Susan K. Loftin is a scholar working on Neurology, Oncology and Cellular and Molecular Neuroscience, having authored 22 papers that have together received 4.5k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (12 papers), Neurological disorders and treatments (9 papers) and Viral-associated cancers and disorders (6 papers). The work is most often cited by research in Oncology (2.7k citations), Immunology (1.9k citations) and Epidemiology (1.5k citations). Susan K. Loftin has collaborated with scholars based in United States, Italy and Lebanon. Frequent co-authors include Cliona M. Rooney, Robert A. Krance, Catherine Y. Ng, Malcolm K. Brenner, Helen E. Heslop, Colton A. Smith, Malcolm K. Brenner, Yan‐jun Gan, John W. Sixbey and Deo Kumar Srivastava. Their work appears in journals such as The Lancet, Nature Medicine and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact